ArriVent BioPharma, Inc. AVBP Total debt

Total debt at other companies

Johnson & JohnsonJNJ

$49.04B-3.4%

Oric Pharmaceuticals, Inc.ORIC

$3.3M+2.6%

Syndax PharmaceuticalsSNDX

$350.49M+4.2%

Nuvation BioNUVB

$9.52M-83.5%

Inhibrx Biosciences, Inc.INBX

$180.9M+69.8%

Bicara TherapeuticsBCAX

$1.44M+144%

FAQ

What is ArriVent BioPharma, Inc.'s total debt?

ArriVent BioPharma, Inc. (AVBP) reported total debt of $419K in Q1 2026.

How has ArriVent BioPharma, Inc.'s total debt changed year-over-year?

ArriVent BioPharma, Inc.'s total debt increased by 203.6% year-over-year, from $138K to $419K.

What is the long-term trend for ArriVent BioPharma, Inc.'s total debt?

Over 2 years (2023 to 2025), ArriVent BioPharma, Inc.'s total debt has grown at a -79.0% compound annual growth rate (CAGR), from $317K to $14K.

What does total debt mean?

Total debt represents the aggregate sum of all interest-bearing financial obligations, including short-term borrowings, the current portion of long-term debt, and long-term debt instruments. It also encompasses capitalized lease liabilities and other debt-like financing arrangements that require fixed repayment schedules. This metric serves as a comprehensive indicator of a company's total financial leverage and its reliance on external capital providers.